WO2009116529A1 - ポリペプチドおよび当該ポリペプチドを含む医薬組成物 - Google Patents
ポリペプチドおよび当該ポリペプチドを含む医薬組成物 Download PDFInfo
- Publication number
- WO2009116529A1 WO2009116529A1 PCT/JP2009/055165 JP2009055165W WO2009116529A1 WO 2009116529 A1 WO2009116529 A1 WO 2009116529A1 JP 2009055165 W JP2009055165 W JP 2009055165W WO 2009116529 A1 WO2009116529 A1 WO 2009116529A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polypeptide
- amino acid
- angiogenesis
- acid sequence
- pedf
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to a polypeptide effective for treating or preventing a disease involving angiogenesis, an angiogenesis inhibitor containing the polypeptide as an active ingredient, or a pharmaceutical composition containing the polypeptide.
- angiogenesis In the human body, angiogenesis is controlled under the strict control of the functional balance between factors that promote angiogenesis and factors that inhibit angiogenesis, such as wound healing and the appropriate stages of the menstrual cycle. Induced only at the time or site.
- angiogenesis is induced in many solid tumors, and the newly formed blood vessels supply blood to tumor cells to grow the tumor and cause damage to normal tissues around it. It is also known to promote tumor cell metastasis to other sites and tissues.
- VEGF vascular endothelial growth factor
- HIF-1 hypoxia-inducible factor 1
- Ang1 angiopoietin-1
- Ang2 Angiopoietin-2
- Flt-1 and FLk-1 / KDR receptors which are a type of transmembrane protein tyrosine kinase expressed on the surface of endothelial cells, also bind to VEGF and cause cell signals that ultimately cause angiogenesis in surrounding tissues. Since they cause a cascade, they can also be understood as factors that promote angiogenesis.
- PEDF pigment epithelium-derived factor
- endostatin TIMP-3 and the like
- these anti-angiogenic factors suppress angiogenesis and exert a certain therapeutic effect when administered to a site where angiogenesis is induced.
- suppression of capillary angiogenesis in retinal epithelial cells has been confirmed in a model animal administered with an adeno-associated virus vector expressing PEDF (Patent Document 1).
- angiogenesis is also suppressed in model animals administered with an angiostatin-expressing adeno-associated virus vector, and subretinal injection of endostatin in a mouse model of retinopathy of prematurity also suppresses retinal angiogenesis. It is known to do each (Patent Document 2).
- PEDF Non-patent Document 1
- Patent Documents 1, Patent Document 3, etc.
- Patent Document 4 uses PEDF or a polypeptide having a 44 amino acid residue consisting of the 78th to 121st amino acid sequences of PEDF (PEDF44AA peptide) for the treatment of a disease associated with enhanced vascular permeability or angiogenesis.
- PEDF44AA peptide all the physiological functions recognized by PEDF are present in the 44 amino acid region, and in particular, specific amino acid residues are essential for the functional expression of PEDF and PEDF44AA peptides. I conclude.
- An object of the present invention is to provide a novel polypeptide capable of suppressing angiogenesis and use thereof.
- the present inventors have surprisingly found that the region around amino acids 78 to 121 of PEDF is completely different from the vicinity of the C-terminal end of PEDF.
- the inventors have found that a polypeptide containing a specific amino acid sequence located at has an anti-angiogenic effect, and completed the following inventions. That is, the present invention is as follows.
- a polypeptide having an angiogenesis inhibitory action comprising any one or more amino acid sequences represented by SEQ ID NOs: 1 to 3 and having 120 or less amino acid residues.
- polypeptide (P5) according to (3), comprising the amino acid sequence represented by SEQ ID NO: 5.
- polypeptide (P5-1 to 3) comprising any one of the amino acid sequences represented by SEQ ID NOs: 1 to 3.
- a therapeutic agent for psoriasis comprising, as an active ingredient, a polypeptide (PEDF) comprising the amino acid sequence represented by SEQ ID NO: 6 and having an angiogenesis inhibitory action.
- PEDF polypeptide
- An angiogenesis inhibitor comprising the polypeptide according to any one of (1) to (5) as an active ingredient.
- a therapeutic agent for psoriasis comprising the polypeptide according to any one of (1) to (5) as an active ingredient.
- a tumor cell growth inhibitor comprising the polypeptide according to any one of (1) to (5) as an active ingredient.
- a pharmaceutical composition for inhibiting angiogenesis comprising the polypeptide according to any one of (1) to (5) and a pharmaceutically acceptable carrier or excipient.
- a pharmaceutical composition for treating psoriasis comprising the polypeptide according to any one of (1) to (5) and a pharmaceutically acceptable carrier or excipient.
- the polypeptide of the present invention is a polypeptide having a lower molecular weight than PEDF, which retains angiogenesis-inhibiting action, and can overcome the defense mechanism against foreign body invasion of living bodies such as skin barriers. It is characterized by excellent permeability or absorbability to the affected area.
- lower molecular weight polypeptides can be produced by chemical synthesis, and can be produced at lower cost and in larger quantities than the production of PEDF, which requires recombinant production. Can be greatly reduced.
- a low molecular weight polypeptide is generally excellent in stability compared to a protein or the like that is a macromolecule, and is advantageous in using the polypeptide as a pharmaceutical having various forms.
- FIG. 3 is a graph showing the growth inhibitory effect of polypeptides P1 to P6 on human osteosarcoma cells MG63.
- Con represents a control to which PBS was added.
- FIG. 3 is a graph showing the growth inhibitory effect of polypeptides P5-1 to P5-3 on human osteosarcoma cells MG63. Con represents a control to which PBS was added.
- Con represents a control to which PBS was added. It is a graph which shows the change of the thickness of the skin derived from the psoriasis patient transplanted to the mouse
- Control peptide represents a control to which a peptide having a random sequence was added. It is a graph which shows the change of the capillary endothelial cell number of the skin derived from the psoriasis patient transplanted to the mouse
- Control peptide represents a control to which a peptide having a random sequence was added.
- the present invention provides a polypeptide having an angiogenesis-inhibiting action, comprising any one or more amino acid sequences represented by SEQ ID NOs: 1 to 3 and having 120 or less amino acid residues.
- a preferred embodiment of the above polypeptide is a polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 4.
- this polypeptide is represented as F3.
- the amino acid sequence of F3 is identical to the 301st to 418th amino acid sequences of PEDF (the entire amino acid sequence is shown in SEQ ID NO: 6).
- polypeptide has an angiogenesis-inhibiting action comprising any one or two or more amino acid sequences shown in SEQ ID NOs: 1 to 3 and having 20 or less amino acid residues. More preferably, it is a polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 5. Hereinafter, this polypeptide is represented as P5.
- the amino acid sequence of P5 is identical to the amino acid sequence from 381 to 400 of PEDF.
- the most preferred embodiment of the above polypeptide is a polypeptide having an angiogenesis-inhibiting action consisting of any one or more amino acid sequences shown in SEQ ID NOs: 1 to 3.
- the amino acid sequence shown in SEQ ID NO: 1 is the amino acid sequence from 381 to 387 of the amino acid sequence of PEDF
- the amino acid sequence shown in SEQ ID NO: 2 is the amino acid sequence from the 388th to 394th of the amino acid sequence of PEDF.
- the amino acid sequence shown in SEQ ID NO: 3 is the same as the amino acid sequence from the 395th to the 400th amino acid sequence of PEDF.
- a polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 1 is P5-1
- a polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 2 is P5-2
- a polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 3 is P5. -3, respectively.
- the polypeptide of the present invention has the activity of suppressing the growth of human osteosarcoma cells, MG63 cells or HUVECs (normal human umbilical vein endothelial cells), as in PEDF, as shown in the Examples below. .
- “suppressing angiogenesis” and “angiogenesis inhibitor” are used interchangeably with “inhibiting angiogenesis” and “angiogenesis inhibitor”. Therefore, “angiogenesis-inhibiting action” can be expressed as “angiogenesis-inhibiting action”, and “angiogenesis-inhibiting agent” can also be expressed as “angiogenesis-inhibiting agent”.
- the site responsible for the function of PEDF is the 78th to 121st amino acid sequence portion located on the N-terminal side of PEDF.
- This 78th to 121st amino acid sequence is an amino acid sequence that is completely different from the amino acid sequence constituting the polypeptide of the present invention, and the two amino acid sequences do not overlap at all on PEDF. It is rare that a so-called “active center” of a functional protein such as PEDF exists independently at different positions of a single protein, and the present invention has so far been known for the structure-function relationship of PEDF. It gives a completely new knowledge that was not available.
- F3 is an example of “an angiogenesis-inhibiting action polypeptide comprising any one or more amino acid sequences represented by SEQ ID NOs: 1 to 3 and having 120 or less amino acid residues”
- an amino acid residue in which one or several amino acids other than the amino acid sequence corresponding to any of SEQ ID NOs: 1 to 3 are substituted or deleted, or an amino acid residue relative to the amino acid sequence of F3 Any polypeptide consisting of an amino acid sequence to which an amino acid has been added in a range not exceeding 120 as a radix is included in the present invention as long as the anti-angiogenic effect is maintained.
- P5 is an example of “a polypeptide having an angiogenesis-inhibiting action, comprising any one or more amino acid sequences represented by SEQ ID NOs: 1 to 3 and having 20 or less amino acid residues”.
- amino acid sequence of P5 an amino acid sequence in which one or several amino acids other than the amino acid sequence corresponding to any of SEQ ID NOs: 1 to 3 are substituted or deleted, or an amino acid residue with respect to the amino acid sequence of P5
- Any polypeptide consisting of an amino acid sequence to which amino acids are added within a range not exceeding 120 is included in the present invention as long as the anti-angiogenic effect is maintained.
- “One or several” amino acid sequence substitutions and deletions in F3 are within 1 to several tens of amino acids, preferably within 1 to 30, more preferably within 1 to 20 and even more preferably 1 to 10 Within 1 and most preferably within 1 to 5. Moreover, when expressed in terms of identity (%) of amino acid sequences based on the amino acid sequence of F3, it is 80% or more, preferably 85% or more, more preferably 90% or more, and particularly preferably 95% with respect to each amino acid sequence. It can represent as an amino acid sequence which has the above identity. Further, “one or several” relating to amino acid sequence substitution and deletion in P5 means within 1 to 10 amino acids, preferably within 1 to 5 and more preferably within 1 to 3.
- amino acid sequences when expressed in terms of identity (%) of amino acid sequences based on the amino acid sequence of F3, it is 80% or more, preferably 85% or more, more preferably 90% or more, and particularly preferably 95% with respect to each amino acid sequence. It can represent as an amino acid sequence which has the above identity.
- amino acid sequence of a protein can tolerate highly conservative mutations in physicochemical properties such as charge, size, and hydrophobicity of amino acid residues.
- substitution of amino acid residues glycine (Gly) and proline (Pro), Gly and alanine (Ala) or valine (Val), leucine (Leu) and isoleucine (Ile), glutamic acid (Glu) and glutamine (Gln) ), Aspartic acid (Asp) and asparagine (Asn), cysteine (Cys) and threonine (Thr), Thr and serine (Ser) or Ala, lysine (Lys) and arginine (Arg), and the like.
- polypeptide of the present invention even a polypeptide comprising an amino acid sequence in which one or several amino acids are substituted, deleted, and / or added may have an anti-angiogenic action. Such polypeptides are still understood as an aspect of the present invention.
- the polypeptide of the present invention is produced or used as a so-called fusion polypeptide in which a polypeptide having a function different from the function of the polypeptide of the present invention is added to the N-terminus and / or C-terminus thereof. May be.
- a fusion polypeptide is also an embodiment of the present invention.
- Such a fusion polypeptide may have increased utility as compared to the case where the polypeptide of the present invention is produced or used alone in that the function of the added polypeptide is further added.
- Examples of such functional polypeptides include glutathione-S-transferase, fluorescent protein, FLAG tag, histidine tag or chitin binding sequence.
- an appropriate labeling compound such as a fluorescent substance or a radioactive substance may be added to the polypeptide of the present invention, or various chemical modifiers or polymers such as polyethylene glycol may be bound as necessary. It is possible, or the polypeptide of the present invention can be bound to an insoluble carrier. Chemical modification methods targeting such polypeptides are widely known to those skilled in the art and may be modified and used in any way as long as the functions of the polypeptides used in the present invention are not impaired. In addition, since the polypeptide of the present invention exhibits an angiogenesis inhibitory action in a form that is not subjected to sugar chain modification, it is not always necessary to perform sugar chain modification on the polypeptide of the present invention.
- the angiogenesis inhibitory action of the polypeptide of the present invention can be confirmed, for example, by confirming the growth inhibitory action on HUVECs performed in Examples described later, as well as an angiogenesis inhibitory activity assay method by the mouse cornea method (Ushiro et al., FEBS Lett., 1997, 418, 341-345), commercially available angiogenesis kit (AngiogenesisesKit, Kurabo), assay using chicken fertilized egg chorioallantoic membrane (Ausprunk et al., Am. J. Pathol., 1975) 97, 597), etc., can be confirmed using methods known to those skilled in the art.
- the polypeptide of the present invention can be produced recombinantly using a nucleic acid encoding the polypeptide.
- the nucleic acid used for the recombinant production is preferably DNA, the nucleotide sequence is determined based on the amino acid sequence of the polypeptide of the present invention, and is synthesized by chemical synthesis such as phosphoramidite method, or using a commercially available DNA synthesizer.
- the polypeptide of the present invention can be produced recombinantly by incorporating the thus prepared nucleic acid, preferably DNA, into an appropriate expression vector, and further transforming an appropriate host cell such as E. coli with the vector. Can do.
- Methods for producing such polypeptides using genetic recombination techniques include nucleic acid preparation, selection of promoters, etc., production of recombinant vectors, host-vector system combinations, transformation of host cells, and culture methods and conditions. Until now, many different methods have been developed and used. Many kits for carrying out such a method easily are commercially available. When the polypeptide of the present invention is produced recombinantly, any such recombinant technique can be used, and specific operations are attached to many experimental operation manuals, kits and reagents. Just follow the protocol.
- the polypeptide of the present invention can be used only at a specific site in the living body. Can be expressed and produced to exert the function of the polypeptide of the present invention.
- tissue-specific or organ-specific gene expression techniques are also widely known to those skilled in the art, and any of these techniques can be used for the use of the polypeptide of the present invention.
- the polypeptide of the present invention can be obtained by, for example, Fmoc method (fluorenylmethyloxycarbonyl method), tBoc method (t-butyloxycarbonyl method), other organic chemical synthesis methods, or a suitable commercially available peptide synthesizer. It can also be produced by using it. In particular, in the production of a relatively low molecular weight polypeptide such as P5-1 to 3, it is preferable to produce the polypeptide by organic chemical synthesis because it can be synthesized in large quantities.
- polypeptides of the present invention may be synthesized according to such methods.
- synthesized polypeptide is as designed can be confirmed using an amino acid analyzer, a high-resolution MS method such as MALDI-TOF-MS, an amino acid sequencer, or the like. Furthermore, the synthesized polypeptide is preferably used after purification as necessary, for example, using a high performance liquid chromatograph (HPLC) or the like.
- HPLC high performance liquid chromatograph
- the present invention provides a pharmaceutical composition for inhibiting angiogenesis comprising the polypeptide and a pharmaceutically acceptable carrier or excipient.
- the present invention also provides a psoriasis therapeutic agent comprising the polypeptide as an active ingredient, a pharmaceutical composition for treating psoriasis comprising the polypeptide and a pharmaceutically acceptable carrier or excipient.
- the pharmaceutical composition comprises the polypeptide of the present invention and one or more pharmaceutically acceptable carriers, or one or more excipients, and is further used as an additive component widely used in pharmaceutical compositions. Furthermore, a medicinal component other than the polypeptide of the present invention may be contained.
- a pharmaceutical composition can be prepared as an oral preparation, an external preparation, a transdermal preparation, a transmucosal agent, an eye drop, an injection, and other preparations suitable for various administration routes.
- the pharmaceutical composition of the present invention can also be prepared in other forms such as solid preparations, solutions, suspensions, emulsion preparations, ointments, liposome preparations, sustained-release preparations.
- Such a pharmaceutical composition can be formulated by a formulation technique known or well known to those skilled in the art.
- the pharmaceutical composition of the present invention is preferably formulated in the form of an external preparation.
- External preparations can be prepared as ointments, solutions, lotions, creams, patches, sprays, emulsified preparations and other forms.
- the polypeptide of the present invention has a size of 120 amino acid residues or less, has higher absorbability beyond the skin barrier as compared with general proteins, and is suitable for use as an external preparation.
- the dosage of the pharmaceutical composition of the present invention is appropriately determined according to the judgment of a doctor based on the state of the disease, age, and other medical factors that require administration of the pharmaceutical, but is included in the pharmaceutical composition.
- the amount of the polypeptide of the present invention is generally adjusted within the range of 0.1 to 99% (w / w) per weight of the composition, and the dosage of the pharmaceutical composition may be adjusted as necessary.
- the polypeptide of the present invention has physiological activity equivalent to that of PEDF as described in the examples described later, and can be used for various diseases recognized for PEDF.
- the polypeptide of the present invention has an action of suppressing angiogenesis, and is effective for the treatment of diseases associated with undesirable angiogenesis.
- Diseases with undesirable angiogenesis that can be treated using the polypeptides of the present invention include malignant neoplasms (tumors), malignant melanoma, arteriosclerosis, rheumatoid arthritis, diabetic retinopathy, angiogenesis Type age-related macular degeneration, psoriasis vulgaris, etc. are included, but are not limited to these.
- the polypeptide of the present invention is effective for the treatment of psoriasis vulgaris.
- Psoriasis is a skin disease characterized by the appearance of erythematous dry spots mainly covered with grayish white or silvery white scales on the skin and accompanied by the formation of capillaries in the dermis.
- the exposed skin rash is a disease that significantly lowers the patient's QOL and may develop fever with joint symptoms and pustules.
- compositions for psoriasis include emollients, salicylic acid, topical steroids, vitamin D3 topical (calcipotriol), etretinate, or cyclosporine, and psoralen. And photochemotherapy using long wavelength ultraviolet radiation is also sometimes used.
- these treatments are not always satisfactory in terms of therapeutic effects, and there are many cases accompanied by side effects such as skin irritation.
- steroid external preparations have side effects such as skin atrophy
- vitamin D3 external preparations have hypercalcemia, etc.
- cyclosporine has side effects such as kidney damage.
- the polypeptide of the present invention or a pharmaceutical composition containing the polypeptide is a pharmaceutical comprising a polypeptide derived from a human protein as an active ingredient, having excellent effects and having few side effects. As a new pharmacological treatment for psoriasis vulgaris.
- Example 1> 1 Preparation of cDNA encoding PEDF According to the method described in Yamagishi et al. (Biochem. Biophys. Res. Commun., 2002, 296, 877-882), human placenta cDNA library (Clontech) PCR was performed using the following set of primer DNAs.
- Primer 1F 5′-CTCAGTGTGCAGGCTTAGAG-3 ′ (SEQ ID NO: 7)
- Primer 1R 5′-CCTTCGGTTCCTTGTGGAATC-3 ′ (SEQ ID NO: 8)
- An amplification product of about 1300 bp was recovered from the agarose gel and ligated to the SmaI site of pBluescript IIKS. The resulting construct was verified by restriction enzyme digestion and sequencing. The fragment cut and recovered from this vector with XbaI and HindIII was cloned between the NheI (blunted) and XbaI sites of pBK-CMV (Stratagene), and the expression vector pBK-CMV-PEDF having a cDNA encoding PEDF. A plasmid was prepared.
- the DNA fragment amplified by the primers 2F and 2R is the polypeptide (F1) consisting of the 1st to 160th amino acid sequences of PEDF, and the DNA fragment amplified by the primers 3F and 3R is the 161st to 300th amino acids of PEDF.
- the DNA fragment obtained by amplifying the polypeptide (F2) consisting of the sequence with the primers 4F and 4R encodes the polypeptide (F3) consisting of the 301st to 418th amino acid sequences of PEDF, respectively.
- the amplification products obtained by the PCR reaction were purified, cleaved with NdeI and SalI, and ligated to the multicloning site of pGEX-6P-1 (Amersham Biosciences), which was also opened with NdeI and SalI, and F1 to F3.
- the vectors pGEX-6P-F1 to -F3 expressing each of the above were obtained. Furthermore, polypeptides F1 to F3 were prepared from E. coli (JM109) transformed with each vector according to the method described in Walker et al. (Biotechnology, 1994, Vol. 12, pp. 601-605).
- polypeptides P1 to P6 consisting of amino acid sequences obtained by dividing the amino acid sequence of PEDF from the 301st position to the 418th position every 20 amino acid residues (P6 is only 16 amino acid residues) are converted into peptide synthesizers (Sigma). -Aldrich) was chemically synthesized by Fmoc solid phase synthesis.
- polypeptides P5-1 to P5-3 consisting of amino acid sequences 381 to 387, 388 to 394, and 395 to 400 of the amino acid sequence of PEDF were chemically synthesized using a peptide synthesizer. In FIG. 1, arrangement
- MG63 was suspended in DMEM medium (Dulbecco's modified Eagle's medium, hereinafter simply referred to as medium) containing 10% fetal bovine serum (FBS), 100 units / mL penicillin and streptomycin, and commercially available PEDF protein (Sigma) 100 nM and 100 nM / medium of each of the polypeptides F1 to F3 prepared in “1) Preparation of polypeptides F1 to F3” in Example 1 were added and incubated at 37 ° C. for 24 hours. Subsequently, [ 3 H] thymidine (Amersham Bioscience) by MG63 was added and cultured for 4 hours, and then the amount of uptake was measured to examine the growth inhibitory effect on tumor cells. The result is shown in FIG.
- DMEM medium Dulbecco's modified Eagle's medium, hereinafter simply referred to as medium
- FBS fetal bovine serum
- PEDF protein commercially available PEDF protein
- HUVECs normal human umbilical vein endothelial cells
- 10 3 cells / 100 ⁇ L of HUVECs were seeded in each well of a 96-well plate, and a commercially available PEDF protein consisting of the amino acid sequence shown in SEQ ID NO: 6 (Sigma) 100 nM, 100 ng / mL of VEGF (R & D systems) and 100 nM of polypeptides P5-1 to P5-3 were added to each well, incubated at 37 ° C. under 5% CO 2 for 2 to 4 days. The amount of bromo-2'deoxyuridine incorporation was measured. The result is shown in FIG.
- polypeptides P5-1 to P5-3 significantly suppressed the proliferation of HUVECs compared to the control to which PEDF protein was added (FIG. 5, p ⁇ 0.01).
- CD31 which is a marker protein of capillary endothelial cells is indicated as an index.
- the number of capillary endothelial cells in the superficial dermis of the transplanted skin was measured by immunoassay using rat anti-mouse CD31 antibody. The result is shown in FIG.
- the back hair of 7-8 week old SCID mice was shaved by about 1 cm 2 , and the total thickness of the skin holding the vessel plexus on the fascia covering the back muscles was peeled off.
- the affected skin of a psoriasis patient and the skin of a healthy person sampled according to regulations were washed with PBS containing 1% penicillin and 1% amphotericin B, and then transplanted separately to the skin exfoliation part of the mouse.
- FIG. 8 (photograph) and FIG. 9 show the result of the affected skin of a psoriasis patient
- FIG. 10 photograph
- FIG. 9 and FIG. 11 the thickness of the healthy skin and the affected skin of the infected patient were both significantly reduced (FIG. 9 and FIG. 11, both p ⁇ 0. 05).
- the number of capillary endothelial cells was measured using CD31 as an index by performing the same operation as described above.
- the result of the affected skin of a psoriasis patient is shown in FIG. 12, and the result of a healthy person's skin is shown in FIG.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
1)PEDFをコードするcDNAの調製
Yamagishiら(Biochem.Biophys.Res.Commun.、2002年、第296巻、第877-882頁)に記載された方法に従い、ヒト胎盤cDNAライブラリー(Clontech社)に対して下記の一組プライマーDNAを用いてPCRを行った。
プライマー1F:5’-CTCAGTGTGCAGGCTTAGAG-3’(配列番号7)
プライマー1R:5’-CCTTCGTGTCCTGTGGAATC-3’(配列番号8)
1)で作製したベクターを鋳型とし、下記の3組のプライマーDNAを用いてPCRを行った。
プライマー2F:5’-AAACATATGCAGGCCCTGGTGCTACTCCTCTGCAT-3’(配列番号9)
プライマー2R:5’-CCCGTCGACTTATGACTTTTCCAGAGGTGCCACAAA-3’(配列番号10)
プライマー3F:5’-AAACATATGTATGGGACCAGGCCCAGAGTCCTGA-3’(配列番号11)
プライマー3R:5’-CCCGTCGACTTAGTCATGAATGAACTCGGAGGTGA-3’(配列番号12)
プライマー4F:5’-GGGCATATGATAGACCGAGAACTGAAGACCGTGCA-3’(配列番号13)
プライマー4R:5’-AAAGTCGACTTAGGGGCCCCTGGGGTCCAGAAT-3’(配列番号14)
Takenakaら(Life Science、2005年、第77巻、第3231-3241頁)に記載された方法に従い、ヒト骨肉腫細胞MG63(Health Science Research Resources)に対する、各ポリペプチドの腫瘍細胞増殖抑制効果を測定した。
103cells/100μLのHUVECsを96ウェルプレートの各ウェルに播き、配列番号6に示されるアミノ酸配列からなる市販のPEDFタンパク質(Sigma社)100nM、VEGF(R&Dsystems社)100ng/mLおよびポリペプチドP5-1~P5-3各100nMをそれぞれウェルに加え、37℃、5%CO2の条件下で2~4日間インキュベートし、HUVECsによる5-ブロモ-2’デオキシウリジン取込量を測定した。その結果を図5に示す。
7~8週齢のSCIDマウス(Clea社)の背毛を1cm2ほど刈り取り、さらに背筋肉を覆う筋膜上のvessel plexusを保持した皮膚全厚を剥離した。倫理規定に基づいてサンプリングした乾癬患者の患部皮膚を1%ペニシリン、1%ストレプトマイシン、1%アンホテリシンBを含むPBSで洗浄し、前記マウスの皮膚剥離部に別々に移植した。
Claims (12)
- 配列番号1~3に示されるいずれか1種または2種以上のアミノ酸配列を含み、かつアミノ酸残基数が120以下である、血管新生抑制作用を有するポリペプチド。
- 配列番号4に示されるアミノ酸配列からなる、請求項1に記載のポリペプチド。
- アミノ酸残基数が20以下である、請求項1に記載のポリペプチド。
- 配列番号5に示されるアミノ酸配列からなる、請求項3に記載のポリペプチド。
- 配列番号1~3に示されるいずれかのアミノ酸配列からなる、請求項1に記載のポリペプチド。
- 配列番号6に示されるアミノ酸配列からなり血管新生抑制作用を有するポリペプチドを有効成分とする乾癬治療剤。
- 請求項1~5のいずれかに記載のポリペプチドを有効成分とする血管新生抑制剤。
- 請求項1~5のいずれかに記載のポリペプチドを有効成分とする乾癬治療剤。
- 請求項1~5のいずれかに記載のポリペプチドを有効成分とする腫瘍細胞増殖抑制剤。
- 請求項1~5のいずれかに記載のポリペプチドおよび薬学的に許容される担体もしくは賦形剤を含む、血管新生抑制用医薬組成物。
- 請求項1~5のいずれかに記載のポリペプチドおよび薬学的に許容される担体もしくは賦形剤を含む、乾癬治療用医薬組成物。
- 外用剤である、請求項10または11に記載の医薬組成物。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2009227206A AU2009227206A1 (en) | 2008-03-18 | 2009-03-17 | Polypeptide and pharmaceutical composition containing the polypeptide |
US12/922,744 US20110092427A1 (en) | 2008-03-18 | 2009-03-17 | Polypeptide and pharmaceutical composition containing the polypeptide |
CN2009801098235A CN101977931A (zh) | 2008-03-18 | 2009-03-17 | 多肽及包含该多肽的药物组合物 |
JP2010503881A JPWO2009116529A1 (ja) | 2008-03-18 | 2009-03-17 | ポリペプチドおよび当該ポリペプチドを含む医薬組成物 |
EP09722434A EP2275437A4 (en) | 2008-03-18 | 2009-03-17 | POLYPEPTIDE AND PHARMACEUTICAL COMPOSITION CONTAINING THE POLYPEPTIDE |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008-070434 | 2008-03-18 | ||
JP2008070434 | 2008-03-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009116529A1 true WO2009116529A1 (ja) | 2009-09-24 |
Family
ID=41090930
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2009/055165 WO2009116529A1 (ja) | 2008-03-18 | 2009-03-17 | ポリペプチドおよび当該ポリペプチドを含む医薬組成物 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20110092427A1 (ja) |
EP (1) | EP2275437A4 (ja) |
JP (1) | JPWO2009116529A1 (ja) |
CN (1) | CN101977931A (ja) |
AU (1) | AU2009227206A1 (ja) |
WO (1) | WO2009116529A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9884012B2 (en) | 2012-08-09 | 2018-02-06 | Mackay Memorial Hospital | Use of PEDF-derived polypeptides for promoting muscle or tendon regeneration or arteriogenesis |
CN115364199A (zh) * | 2021-05-19 | 2022-11-22 | 远大医药(中国)有限公司 | 包含pedf衍生的短肽的组合物及其制备方法和用途 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004516001A (ja) | 2000-02-23 | 2004-06-03 | ノースウエスタン・ユニバーシテイ | 新脈管形成を阻害するための方法および組成物 |
JP2004517117A (ja) | 2001-01-05 | 2004-06-10 | バイロメッド・リミテッド | 抗血管新生タンパク質をコードする遺伝子またはその部分を含む慢性関節リウマチ治療用医薬組成物 |
JP2007509984A (ja) | 2003-10-29 | 2007-04-19 | ザ・ジョンズ・ホプキンス・ユニバーシティ | 色素上皮由来因子、その新規な生物活性及びその使用方法 |
JP2007528903A (ja) | 2004-03-12 | 2007-10-18 | ジェンベク、インコーポレイティッド | 眼における血管漏出を処置するための物質 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6451763B1 (en) * | 1992-06-04 | 2002-09-17 | The United States Of America As Represented By The Department Of Health And Human Services | Retinal pigmented epithelium derived neurotrophic factor and methods of use |
IL147444A0 (en) * | 2002-01-03 | 2002-08-14 | Yeda Res & Dev | Process for the production of pigment epithelium derived factor (pedf) from human blood and uses thereof |
AU2004308484A1 (en) * | 2003-12-23 | 2005-07-14 | The Trustees Of The University Of Pennsylvania | Compositions and methods for combined therapy of disease |
US8106010B2 (en) * | 2005-11-14 | 2012-01-31 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Variants of pigment epithelium derived factor and uses thereof |
US20100120627A1 (en) * | 2006-08-02 | 2010-05-13 | Abdelmajid Belouchi | Genemap of the human genes associated with psoriasis |
-
2009
- 2009-03-17 AU AU2009227206A patent/AU2009227206A1/en not_active Abandoned
- 2009-03-17 WO PCT/JP2009/055165 patent/WO2009116529A1/ja active Application Filing
- 2009-03-17 JP JP2010503881A patent/JPWO2009116529A1/ja active Pending
- 2009-03-17 CN CN2009801098235A patent/CN101977931A/zh active Pending
- 2009-03-17 US US12/922,744 patent/US20110092427A1/en not_active Abandoned
- 2009-03-17 EP EP09722434A patent/EP2275437A4/en not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004516001A (ja) | 2000-02-23 | 2004-06-03 | ノースウエスタン・ユニバーシテイ | 新脈管形成を阻害するための方法および組成物 |
JP2004517117A (ja) | 2001-01-05 | 2004-06-10 | バイロメッド・リミテッド | 抗血管新生タンパク質をコードする遺伝子またはその部分を含む慢性関節リウマチ治療用医薬組成物 |
JP2007509984A (ja) | 2003-10-29 | 2007-04-19 | ザ・ジョンズ・ホプキンス・ユニバーシティ | 色素上皮由来因子、その新規な生物活性及びその使用方法 |
JP2007528903A (ja) | 2004-03-12 | 2007-10-18 | ジェンベク、インコーポレイティッド | 眼における血管漏出を処置するための物質 |
Non-Patent Citations (18)
Title |
---|
ABE ET AL., AM. J. PATHOL., vol. 164, no. 4, 2004, pages 1225 - 1232 |
ABE, R. ET AL.: "Role of Anti-angiogenic Factor, Pigment-epithelium-derived Factor (PEDF) in the Pathogenesis of Psoriasis.", J. INVEST. DERMATOL., vol. 126, no. SUP.3, 2006, pages 57, XP009150370 * |
AUSPRUNK ET AL., AM. J. PATHOL., vol. 97, 1975, pages 597 |
BECERRA, S.P. ET AL.: "Pigment Epithelium-derived Factor Behaves Like a Noninhibitory Serpin: Neurotrophic Activity Does Not Require the Serpin Reactive Loop.", J. BIOL. CHEM., vol. 270, no. 43, 1995, pages 25992 - 25999, XP001153115 * |
BECERRA, S.P. ET AL.: "Structure-function Studies on PEDF: A Noninhibitry Serpin with Neurotrophic Activity.", ADV. EXP. MED. BIOL., vol. 425, 1997, pages 223 - 237, XP009150374 * |
BERNARD, A. ET AL.: "Laminin Receptor Involvement in the Anti-angiogenic Activity of Pigment Epithelium-Derived Factor.", J. BIOL. CHEM., vol. 284, no. 16, February 2009 (2009-02-01), pages 10480 - 10490, XP008142286 * |
BODANSZKY: "The Practice of Peptide Synthesis", 1984, SPRINGER-VERLAG |
GILHAR ET AL., AM. J. PATHOL., vol. 168, no. 1, 2006, pages 170 - 175 |
MANIATIS T. ET AL.: "Molecular Cloning, a Laboratory Manual", 1982, COLD SPRING HARBOR LABORATORY |
RIICHIRO ABE ET AL.: "Momaku Johi Yurai Inshi (PEDF) Peptide o Mochiita Kansen Chiryo Gaiyoyaku no Kaihatsu.", NIPPON KANSEN GAKKAI GAKUJUTSU TAIKAI, vol. 23, September 2008 (2008-09-01), pages 134, XP008149632 * |
See also references of EP2275437A4 |
STEELE ET AL., PROC. NATL. ACAD. USA, vol. 90, no. 4, 1993, pages 1526 - 1530 |
STEWART ET AL.: "Solid Phase Peptide Synthesis", 1984, PIERCE CHEMICAL COMPANY |
TAKENAKA ET AL., LIFE SCIENCE, vol. 77, 2005, pages 3231 - 3241 |
TOMBRAN-TINK, J. ET AL.: "PEDF and the Serpins: Phylogeny, Sequence Conservation, and Functional Domains.", J. STRUCT. BIOL., vol. 151, no. 2, 2005, pages 130 - 150, XP004997281 * |
USHIRO ET AL., FEBS LETT., vol. 418, 1997, pages 341 - 345 |
WALKER ET AL., BIOTECHNOLOGY, vol. 12, 1994, pages 601 - 605 |
YAMAGISHI ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 296, 2002, pages 877 - 882 |
Also Published As
Publication number | Publication date |
---|---|
EP2275437A4 (en) | 2011-09-07 |
US20110092427A1 (en) | 2011-04-21 |
AU2009227206A1 (en) | 2009-09-24 |
EP2275437A1 (en) | 2011-01-19 |
JPWO2009116529A1 (ja) | 2011-07-21 |
CN101977931A (zh) | 2011-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107188948B (zh) | 用于诱导组织再生的肽及其应用 | |
JP5856117B2 (ja) | 細胞シグナル伝達タンパク質nell1を用いた、創傷治癒及び筋再生の促進方法 | |
JP2018535964A (ja) | 線維芽細胞増殖因子(fgf)1アナログによるステロイド誘導性高血糖の処置 | |
EP3909974A1 (en) | Human hepatocyte growth factor mutant and uses thereof | |
CN105457016B (zh) | Smad7的治疗应用 | |
US7772204B1 (en) | Perlecan and growth factor for wound and cutaneous injury healing | |
CA2731296A1 (en) | New mutated netrin 4 proteins, fragments thereof and their uses as drugs | |
JP2018522547A (ja) | Il−37バリアント | |
AU2014233219B2 (en) | Methods for treatment of nephrotic syndrome and related conditions | |
WO2009116529A1 (ja) | ポリペプチドおよび当該ポリペプチドを含む医薬組成物 | |
US20080200378A1 (en) | KGF polypeptide compositions | |
AU2008256550B2 (en) | VEGF-D mutants and their use | |
US20070059314A1 (en) | Novel anti-angiogenic agent and its use in particular within the framework of the treatment of cancer | |
AU2006261911B2 (en) | Thrombospondin-1 derived peptides and treatment methods | |
JP2018526987A (ja) | 腫瘍抑制ペプチド | |
CN114096556A (zh) | 表皮生长因子受体(egfr)配体 | |
US20140303093A1 (en) | Micro-utrophin polypeptides and methods | |
US11633456B2 (en) | Compositions and methods for promoting hair growth | |
US9371523B2 (en) | Cell migration regulator | |
EP4032901A1 (en) | Recombinant human neuregulin derivatives and use thereof | |
KR20220139079A (ko) | 세포 투과성 펩타이드 변이체 및 이의 용도 | |
US20200061237A1 (en) | Gilz Formulations for Wound Healing | |
KR20210127618A (ko) | 섬유질환 예방 또는 치료용 재조합 융합 단백질 | |
KR20210154784A (ko) | 섬유질환 예방 또는 치료용 재조합 융합 단백질 | |
CN115957301A (zh) | 一种促进心梗心肌修复的细胞分泌因子及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980109823.5 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09722434 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010503881 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 6549/CHENP/2010 Country of ref document: IN Ref document number: 2009722434 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009227206 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2009227206 Country of ref document: AU Date of ref document: 20090317 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12922744 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: PI0911799 Country of ref document: BR Free format text: COM BASE NA RESOLUCAO 228/09 SOLICITA-SE QUE SEJAM APRESENTADOS NOVOS CDS/DVDS COM AS RESPECTIVAS DECLARACOES E CODIGO ALFANUMERICO, POIS O ARQUIVO DA LISTAGEM DE SEQUEENCIA NAO FOI APRESENTADO NO FORMATO TXT. ALEM DISSO, SOLICITA-SE A REGULARIZACAO DA PROCURACAO, TENDO EM VISTA QUE A APRESENTADA ESTA DATADA DE 02/11/2010, SENDO QUE A PETICAO DE ENTRADA NA FASE NACIONAL OCORREU EM 17/09/2010, E O TEXTO DA MESMA NAO POSSUI CLAUSULA QUE RATIFICA OS ATOS PRATICADOS ANTERIORMENTE. |
|
ENPW | Started to enter national phase and was withdrawn or failed for other reasons |
Ref document number: PI0911799 Country of ref document: BR Free format text: PEDIDO RETIRADO EM RELACAO AO BRASIL POR NAO ATENDER AS DETERMINACOES REFERENTES A ENTRADA DO PEDIDO NA FASE NACIONAL E POR NAO CUMPRIMENTO DA EXIGENCIA FORMULADA NA RPI NO 2278 DE 02/09/2014. |